News - Medical and health professional investment - VC and PE investment business - Shenzhen Efung Investment Management Co. Ltd.

发布时间: 2025 - 09 - 08

Xinyuan Pharmaceutical's Anti-Gout Innovative Drug ABP-671 Achieves Positive Results in Global Phase

On September 8, 2025, according to information from Hangzhou, Zhejiang, and the United States, Xinyuan Pharmaceutical announced very positive results from the global Phase IIb/III clinical trial of ABP-671 for the treatment of gout. This study was a multicenter, randomized, double-blind, allopurinol-positive (Treat-to-Target) and placebo-controlled global study conducted across multiple countries and regions, including the United States, Europe, Australia, Latin America, and Taiwan, with a 6-month primary endpoint evaluation period.The results showed that this clinical trial met all primary an...

浏览次数：0

查看详情>>

发布时间: 2025 - 09 - 03

Commemorating the 80th Anniversary of the Victory of the Chinese People's War of Resistance Against

September 3, 2025 marks the 80th anniversary of the victory in the Chinese People's War of Resistance Against Japanese Aggression and the World Anti-Fascist War. On this important day, which carries great triumph, glorious history, and an indelible spirit, in order to deeply commemorate the revolutionary martyrs and carry forward the great spirit of the Resistance War, the Party Branch Committee of the Communist Party of China at Shenzhen Efung Investment Management Enterprise (Limited Partnership) organized a viewing of the military parade.Through this event, members observed the remarkab...

浏览次数：0

查看详情>>

发布时间: 2025 - 08 - 29

Monthly Health Read | August 2025

Today, on the Qixi Festival, the starry river is bright, and magpies form a bridge for lovers' meeting, symbolizing beautiful connections and journeys. In the vast sea of hard tech investment, the "mutual journey" between Ef Capital and its portfolio companies has also borne fruit.Looking back at August, several biopharmaceutical companies invested by Ef Capital performed outstandingly, achieving a series of breakthroughs in financing progress, clinical updates, and regulatory approvals.Notably, two portfolio companies, 3D Medicines and Kaitao Biotech, "joined hands" in...

浏览次数：0

查看详情>>

发布时间: 2025 - 08 - 21

Joint Efforts! 3D Medicines and Canton Biologics Forge Alliance to Advance tLNP-Delivered in vivo CA

On August 20, 2025, in Shanghai, China, 3D Medicines and Canton Biologics officially signed a strategic cooperation agreement. According to the agreement, the two parties will deepen their collaboration in areas such as targeted lipid nanoparticle (tLNP) delivery, tumor vaccines, and in vivo CAR-T/NK therapies. This collaboration will leverage 3D Medicines' self-developed, proprietary AI+mRNA R&D platform and liposome delivery system (3D-LNP), combined with Canton Biologics' expertise and scale in mRNA manufacturing. The specific implementation will follow subsequent form...

浏览次数：0

查看详情>>